Бронхіальна астма - Міністерство охорони здоров'я України

295. Pharmacological management of asthma. Evidence table 4.25:budesonide vs beclometasone.Edinburgh: 2002. Available from url:http://www.sign.ac.uk/guidelines/published/support/guideline63/index.html296. Pharmacological management of asthma. Evidence table 4.15: mometasone furoate dry powderinhalation evidence. Edinburgh: SIGN; 2002. Available from url:http://www.sign.ac.uk/guidelines/published/support/guideline63/index.html297. Boulet LP, Drollmann A, Magyar P, Timar M, Knight A, Engelstatter R, et al. Comparative efficacy ofonce-daily ciclesonide and budesonide in the treatment of persistent asthma. Respir Med 2006;100(5):785-94.298. Buhl R, Vinkler I, Magyar P, Gyori Z, Rybacki C, Middle MV, et al. Comparable efficacy ofciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol Ther2006;19(6):404-12.299. Niphadkar P, Jagannath K, Joshi JM, Awad N, Boss H, Hellbardt S, et al. Comparison of the efficacy ofciclesonide 160 microg QD and budesonide 200 microg BID in adults with persistent asthma: a phase III,randomized, double-dummy, open-label study. Clin Ther 2005;27(11):1752-63.300. Pearlman DS, Berger WE, Kerwin E, Laforce C, Kundu S, Banerji D.Once-daily ciclesonide improveslung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy ClinImmunol 2005;116(6):1206-12.301. Szefler S, Rohatagi S, Williams J, Lloyd M, Kundu S, Banerji D. Ciclesonide, a novel inhaled steroid,does not affect hypothalamicpituitary-adrenal axis function in patients with moderate-to-severe persistentasthma. Chest 2005;128(3):1104-14.302. Tomlinson JE, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, Thomson NC. Efficacy of lowand high dose inhaled corticosteroid insmokers versus non-smokers with mild asthma. Thorax2005;60(4):282-7.303. Salmeterol (Severant) and formoterol (Oxis) in asthma management. Curr Probl Pharmacovigilanc2003;29(5).304. Edwards A SM. The clinical efficacy of inhaled nedocromil sodium (Tilade) in the treatment of asthma.Eur Respir J 1993;6(1):35-41.305. Pharmacological management of asthma. Evidence table 4.24a: Otherpreventor therapies - Chromonesin children aged 5-12. Edinburgh:SIGN; 2005. Available from url: http://www.sign.ac.uk/guidelines/published/support/guideline63/index.html306. Table 16: nedocromil and sodium cromoglycate studies not included in the nedocromil meta-analysis.In: North of England Evidence Based Guideline Development Project, editor. The primary care managementof asthma in adults. Newcastle upon Tyne: University of Newcastle upon Tyne, Centre for Health ServicesResearch; 1999. p.46-7.307. Pharmacological management of asthma. Evidence table 4.4j: Do cromones works as first linepreventor in children >5 years? Edinburgh: SIGN; 2002. Available from url:http://www.sign.ac.uk/guidelines/published/support/guideline63/index.html308. Pharmacological management of asthma. Evidence table 4.24b: Other preventor therapies - Chromonesin children aged